2.24
前日終値:
$2.21
開ける:
$2.2
24時間の取引高:
1.35M
Relative Volume:
0.45
時価総額:
$767.37M
収益:
$796.85M
当期純損益:
$30.44M
株価収益率:
26.60
EPS:
0.0842
ネットキャッシュフロー:
$93.88M
1週間 パフォーマンス:
-1.75%
1か月 パフォーマンス:
+2.75%
6か月 パフォーマンス:
-46.54%
1年 パフォーマンス:
-49.89%
Goodrx Holdings Inc Stock (GDRX) Company Profile
名前
Goodrx Holdings Inc
セクター
電話
(855) 268-2822
住所
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GDRX
Goodrx Holdings Inc
|
2.24 | 767.37M | 796.85M | 30.44M | 93.88M | 0.0842 |
|
VEEV
Veeva Systems Inc
|
178.88 | 29.40B | 3.20B | 908.91M | 1.42B | 5.4155 |
|
TEM
Tempus Ai Inc
|
49.98 | 8.94B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
38.31 | 7.36B | 12.91B | 104.80M | 394.69M | 0.8769 |
|
HQY
Healthequity Inc
|
77.81 | 6.65B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
24.16 | 4.63B | 1.10B | 112.09M | 283.19M | 0.6096 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2026-01-22 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-08-11 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 開始されました | Mizuho | Neutral |
| 2024-08-09 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 開始されました | Leerink Partners | Outperform |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-08-10 | アップグレード | DA Davidson | Neutral → Buy |
| 2023-07-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 開始されました | Citigroup | Buy |
| 2022-11-04 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-08-12 | 開始されました | DA Davidson | Neutral |
| 2022-06-10 | ダウングレード | Goldman | Buy → Neutral |
| 2022-06-06 | 再開されました | BofA Securities | Buy |
| 2022-06-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-05-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 開始されました | Wells Fargo | Equal Weight |
| 2022-04-07 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Neutral |
| 2022-03-15 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 繰り返されました | Barclays | Overweight |
| 2022-03-01 | 繰り返されました | BofA Securities | Neutral |
| 2022-03-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-03-01 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 繰り返されました | Evercore ISI | Outperform |
| 2022-03-01 | 繰り返されました | Goldman | Buy |
| 2022-03-01 | 繰り返されました | JP Morgan | Underweight |
| 2022-03-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-03-01 | 繰り返されました | SVB Leerink | Outperform |
| 2022-01-07 | 開始されました | Goldman | Buy |
| 2021-12-21 | 開始されました | Stephens | Overweight |
| 2021-12-02 | 開始されました | Jefferies | Buy |
| 2021-08-31 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-08-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 開始されました | Robert W. Baird | Neutral |
| 2021-04-06 | 再開されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Guggenheim | Buy |
| 2020-11-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 開始されました | Barclays | Equal Weight |
| 2020-10-19 | 開始されました | BofA Securities | Neutral |
| 2020-10-19 | 開始されました | Citigroup | Buy |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-10-19 | 開始されました | Credit Suisse | Outperform |
| 2020-10-19 | 開始されました | Deutsche Bank | Hold |
| 2020-10-19 | 開始されました | Goldman | Neutral |
| 2020-10-19 | 開始されました | JP Morgan | Neutral |
| 2020-10-19 | 開始されました | Morgan Stanley | Overweight |
| 2020-10-19 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 開始されました | SVB Leerink | Outperform |
| 2020-10-19 | 開始されました | UBS | Buy |
すべてを表示
Goodrx Holdings Inc (GDRX) 最新ニュース
Lakewood Capital Management LP Decreases Position in GoodRx Holdings, Inc. $GDRX - MarketBeat
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
GoodRx (GDRX) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx approves $72,918 discretionary bonus for Chief Accounting Officer Romin Nabiey - TradingView
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers. - Bitget
GoodRx to expand employer-sponsored access to Zepbound® Kwikpen® - marketscreener.com
Obesity drug Zepbound now offered to workers at $449 through GoodRx - Stock Titan
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GoodRx Announces Resignation of Board Member Dipanjan Deb - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts - simplywall.st
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx (GDRX) board member Dipanjan Deb steps down without dispute - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho - MarketBeat
Hims & Hers Expands Digital Health and Global Platform Strategy - TradingView
GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says - marketscreener.com
UBS Lowers Price Target on GoodRx Holdings to $2 From $4, Maintains Neutral Rating - marketscreener.com
Raymond James cuts GoodRx stock price target on pharma headwinds - Investing.com Nigeria
Raymond James cuts GoodRx stock price target on pharma headwinds By Investing.com - Investing.com Australia
JPMorgan Chase & Co. Reaffirms Neutral Rating for GoodRx (NASDAQ:GDRX) - MarketBeat
A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts - Benzinga
GoodRx Holdings (GDRX) Downgraded by JP Morgan to Neutral | GDRX Stock News - GuruFocus
JPMorgan Downgrades GoodRx to Neutral From Overweight - marketscreener.com
Morgan Stanley Cuts Price Target on GoodRx Holdings to $3 From $4, Keeps Equalweight Rating - marketscreener.com
GDRX: GoodRx drives ~$17B in annual consumer savings and achieves profitable growth with expanding partnerships - TradingView
GoodRx Holdings GDRX Margin Improvement Reinforces Bullish Profitability Narratives - simplywall.st
Goodrx Holdings Inc (GDRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):